BACKGROUND: Bosentan, an oral endothelin (ET)-A/ET-B receptor antagonist, is effective in the treatment of pulmonary arterial hypertension. OBJECTIVE: To investigate the safety and efficacy of bosentan therapy in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). DESIGN: Case series. SETTING:Pulmonary Hypertension Unit of the Medical University of Vienna, Austria. PATIENTS: Sixteen patients (9 women and 7 men; mean age +/- SD, 70 +/- 13 years). INTERVENTION: Off-label bosentan treatment over 6 months. MEASUREMENTS: Changes from baseline in liver enzymes, New York Heart Association (NYHA) functional class, 6-min walking distance (6-MWD), and serum amino-terminal pro-brain natriuretic peptide (proBNP). RESULTS: After 6 months, NYHA functional class improved by one class in 11 patients. Mean 6-MWDs increased from 299 +/- 131 m at baseline to 391 +/- 110 m at 6 months (p = 0.01). In parallel, proBNP decreased from 3,365 +/- 2,923 to 1,755 +/- 1,812 pg/mL (p = 0.01). Neither aspartate aminotransferase (25 +/- 2 U/L vs 25 +/- 2 U/L, p = 0.25) nor alanine aminotransferase (23 +/- 12 U/L vs 24 +/- 9 U/L, p = 0.57) changed significantly. Limitations of the study were uncontrolled design and small sample size. CONCLUSIONS: Our study suggests a beneficial effect of the oral dual ET receptor antagonist bosentan in patients with inoperable CTEPH, urging the need for a randomized, placebo-controlled trial.
RCT Entities:
BACKGROUND:Bosentan, an oral endothelin (ET)-A/ET-B receptor antagonist, is effective in the treatment of pulmonary arterial hypertension. OBJECTIVE: To investigate the safety and efficacy of bosentan therapy in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). DESIGN: Case series. SETTING: Pulmonary Hypertension Unit of the Medical University of Vienna, Austria. PATIENTS: Sixteen patients (9 women and 7 men; mean age +/- SD, 70 +/- 13 years). INTERVENTION: Off-label bosentan treatment over 6 months. MEASUREMENTS: Changes from baseline in liver enzymes, New York Heart Association (NYHA) functional class, 6-min walking distance (6-MWD), and serum amino-terminal pro-brain natriuretic peptide (proBNP). RESULTS: After 6 months, NYHA functional class improved by one class in 11 patients. Mean 6-MWDs increased from 299 +/- 131 m at baseline to 391 +/- 110 m at 6 months (p = 0.01). In parallel, proBNP decreased from 3,365 +/- 2,923 to 1,755 +/- 1,812 pg/mL (p = 0.01). Neither aspartate aminotransferase (25 +/- 2 U/L vs 25 +/- 2 U/L, p = 0.25) nor alanine aminotransferase (23 +/- 12 U/L vs 24 +/- 9 U/L, p = 0.57) changed significantly. Limitations of the study were uncontrolled design and small sample size. CONCLUSIONS: Our study suggests a beneficial effect of the oral dual ET receptor antagonist bosentan in patients with inoperable CTEPH, urging the need for a randomized, placebo-controlled trial.
Authors: Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf Journal: Can Respir J Date: 2010 Nov-Dec Impact factor: 2.409
Authors: Hans-Juergen Seyfarth; Michael Halank; Heinrike Wilkens; Hans-Joachim Schäfers; Ralf Ewert; Martin Riedel; Ernst Schuster; Hans Pankau; Stefan Hammerschmidt; Hubert Wirtz Journal: Clin Res Cardiol Date: 2010-04-25 Impact factor: 5.460
Authors: M G J Duffels; M N van der Plas; S Surie; M M Winter; B Bouma; M Groenink; A P J van Dijk; E Hoendermis; R M F Berger; P Bresser; B J M Mulder Journal: Neth Heart J Date: 2009-09 Impact factor: 2.380
Authors: Nadine Al-Naamani; Gaudalupe Espitia H; Hugo Velazquez-Moreno; Benjamin Macuil-Chazaro; Arturo Serrano-Lopez; Ricardo S Vega-Barrientos; Nicholas S Hill; Ioana R Preston Journal: Lung Date: 2016-01-09 Impact factor: 2.584
Authors: Jay Suntharalingam; Rajiv D Machado; Linda D Sharples; Mark R Toshner; Karen K Sheares; Rodney J Hughes; David P Jenkins; Richard C Trembath; Nicholas W Morrell; Joanna Pepke-Zaba Journal: Thorax Date: 2007-02-07 Impact factor: 9.139